title: Oral gold therapy in steroid-dependent asthma, nasal polyposis, and aspirin hypersensitivity.
abstract: Eight patients are described who fulfill the criteria for the triad of asthma, nasal polyposis, and aspirin hypersensitivity who have been treated with oral chrysotherapy from 7 to 17 months. Patient diary and symptom scores reflect an overall improvement in global symptoms. Monthly pulmonary assessment (spirometry) does not indicate a significant change (improvement or deterioration) but average daily oral prednisone requirements have decreased. One of eight patients experienced a minor side effect of treatment but did not require discontinuation of therapy. Oral gold therapy may prove to be an alternative therapy in a select population of patients and permit a reduction or discontinuation of oral corticosteroid therapy.
authors.affiliation: Division of Immunology, Ohio State University, Columbus.
authors.forename: D L
authors.initials: DL
authors.lastname: McNeil
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology*; D001241:Aspirin / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D001310:Auranofin / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D009298:Nasal Polyps; D011446:Prospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D001310:Auranofin; D001241:Aspirin